Total Payments
$31,945
2024 Payments
$3,336
Companies
20
Transactions
59
Medicare Patients
1,191
Medicare Billing
$218,238
Payment Breakdown by Category
Consulting$15,989 (50.1%)
Research$8,969 (28.1%)
Travel$2,704 (8.5%)
Other$2,510 (7.9%)
Food & Beverage$1,729 (5.4%)
Education$43.72 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $15,989 | 10 | 50.1% |
| Unspecified | $8,969 | 11 | 28.1% |
| Travel and Lodging | $2,704 | 8 | 8.5% |
| Food and Beverage | $1,729 | 24 | 5.4% |
| Honoraria | $1,500 | 1 | 4.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $898.15 | 2 | 2.8% |
| Compensation for serving as faculty or as a speaker for a medical education program | $111.52 | 1 | 0.3% |
| Education | $43.72 | 2 | 0.1% |
Payments by Type
General
$22,976
48 transactions
Research
$8,969
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech, Inc. | $10,096 | 10 | $0 (2024) |
| Gilead Sciences, Inc. | $3,012 | 2 | $0 (2021) |
| Aadi Bioscience, Inc. | $2,878 | 8 | $0 (2022) |
| Ipsen Biopharmaceuticals, Inc | $2,450 | 1 | $0 (2020) |
| Celgene Corporation | $2,385 | 4 | $0 (2018) |
| Eisai Inc. | $2,355 | 1 | $0 (2023) |
| F. Hoffmann-La Roche AG | $2,290 | 5 | $0 (2020) |
| Legend Biotech USA Inc. | $1,460 | 1 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,309 | 4 | $0 (2024) |
| Partner Therapeutics, Inc. | $970.84 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,336 | 12 | Legend Biotech USA Inc. ($1,460) |
| 2023 | $4,916 | 7 | Eisai Inc. ($2,355) |
| 2022 | $7,378 | 11 | Genentech, Inc. ($4,500) |
| 2021 | $2,156 | 4 | Genentech, Inc. ($2,112) |
| 2020 | $4,819 | 4 | Ipsen Biopharmaceuticals, Inc ($2,450) |
| 2019 | $815.64 | 3 | F. Hoffmann-La Roche AG ($655.80) |
| 2018 | $6,935 | 11 | Gilead Sciences, Inc. ($3,000) |
| 2017 | $1,588 | 7 | Halozyme Inc ($548.95) |
All Payment Transactions
59 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Partner Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $65.00 | General |
| 12/13/2024 | Partner Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $49.99 | General |
| 12/13/2024 | Partner Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $48.29 | General |
| 12/13/2024 | Partner Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $24.99 | General |
| 12/12/2024 | Partner Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $307.23 | General |
| 12/12/2024 | Partner Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $272.91 | General |
| 12/12/2024 | Partner Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $150.00 | General |
| 12/12/2024 | Partner Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $52.43 | General |
| 10/09/2024 | Legend Biotech USA Inc. | — | Consulting Fee | Cash or cash equivalent | $1,460.00 | General |
| 07/24/2024 | Genentech, Inc. | Tecentriq (Biological) | — | Cash or cash equivalent | $660.00 | Research |
| Study: Unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy • Category: BioOncology | ||||||
| 06/01/2024 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $133.98 | General |
| 04/12/2024 | AstraZeneca Pharmaceuticals LP | — | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $111.52 | General |
| 12/26/2023 | Genentech, Inc. | Tecentriq (Biological) | — | Cash or cash equivalent | $910.80 | Research |
| Study: Unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy • Category: BioOncology | ||||||
| 11/21/2023 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $2,355.00 | General |
| Category: Oncology | ||||||
| 10/21/2023 | Novocure GmbH | Optune (Device) | Food and Beverage | Cash or cash equivalent | $100.09 | General |
| Category: Oncology | ||||||
| 07/19/2023 | Exelixis Inc. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 07/13/2023 | Genentech, Inc. | Tecentriq (Biological) | — | Cash or cash equivalent | $825.00 | Research |
| Study: Unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy • Category: BioOncology | ||||||
| 06/03/2023 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $124.03 | General |
| 02/23/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $101.35 | General |
| Category: Oncology | ||||||
| 12/15/2022 | Genentech, Inc. | TECENTRIQ (Biological) | — | Cash or cash equivalent | $660.00 | Research |
| Study: UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA FOLLOWING DEFINITIVE CONCURRENT CHEMORADIOTHERAPY • Category: BioOncology | ||||||
| 09/23/2022 | Aadi Bioscience, Inc. | FYARRO (Drug) | Honoraria | Cash or cash equivalent | $1,500.00 | General |
| Category: IMMUNOSUPPRESSANT | ||||||
| 09/23/2022 | Aadi Bioscience, Inc. | FYARRO (Drug) | Travel and Lodging | Cash or cash equivalent | $56.65 | General |
| Category: IMMUNOSUPPRESSANT | ||||||
| 09/23/2022 | Aadi Bioscience, Inc. | FYARRO (Drug) | Food and Beverage | In-kind items and services | $45.91 | General |
| Category: IMMUNOSUPPRESSANT | ||||||
| 09/23/2022 | Aadi Bioscience, Inc. | FYARRO (Drug) | Food and Beverage | In-kind items and services | $44.60 | General |
| Category: IMMUNOSUPPRESSANT | ||||||
| 09/23/2022 | Aadi Bioscience, Inc. | FYARRO (Drug) | Food and Beverage | In-kind items and services | $20.99 | General |
| Category: IMMUNOSUPPRESSANT | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA FOLLOWING DEFINITIVE CONCURRENT CHEMORADIOTHERAPY | Genentech, Inc. | $3,762 | 4 |
| Unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy | Genentech, Inc. | $2,396 | 3 |
| A PHASE IbII, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA MORPHEUS-PANCREATIC CANCER, A PHASE IbII, OPEN-LABEL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL | F. Hoffmann-La Roche AG | $1,313 | 2 |
| STAGE II III ESOPHAGEAL SQUAMOUS CELL CANCERS FOLLOWING CONCURRENT CHEMOTHERAPY AND RADIATION THERAP | Genentech, Inc. | $1,056 | 1 |
| ABI-007-PANC-003 - Phase III Study - PANC-003 (BMS Study Number: CA139-P15) | Celgene Corporation | $442.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 295 | 614 | $407,656 | $63,572 |
| 2022 | 4 | 293 | 526 | $396,314 | $61,292 |
| 2021 | 5 | 325 | 489 | $362,477 | $57,144 |
| 2020 | 5 | 278 | 390 | $281,534 | $36,229 |
Total Patients
1,191
Total Services
2,019
Medicare Billing
$218,238
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 158 | 375 | $289,875 | $46,179 | 15.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 63 | 63 | $68,355 | $10,045 | 14.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 24 | 110 | $17,600 | $3,098 | 17.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 28 | 32 | $18,464 | $2,355 | 12.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 22 | 34 | $13,362 | $1,896 | 14.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 136 | 349 | $269,777 | $43,769 | 16.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 60 | 60 | $65,100 | $9,203 | 14.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 67 | 84 | $48,468 | $6,381 | 13.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 30 | 33 | $12,969 | $1,940 | 15.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 116 | 251 | $194,023 | $32,282 | 16.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 82 | 82 | $88,970 | $13,448 | 15.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 83 | 112 | $64,624 | $9,285 | 14.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 28 | 28 | $11,004 | $1,610 | 14.6% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 16 | 16 | $3,856 | $519.04 | 13.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 100 | 181 | $104,437 | $12,243 | 11.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 67 | 98 | $75,754 | $9,374 | 12.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 61 | 61 | $66,185 | $9,296 | 14.0% |
| 99358 | Prolonged patient service without direct patient contact first hour | Facility | 2020 | 28 | 28 | $16,084 | $2,860 | 17.8% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 22 | 22 | $19,074 | $2,456 | 12.9% |
About Dr. Andrew Ko, MD
Dr. Andrew Ko, MD is a Internal Medicine healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1851355853.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrew Ko, MD has received a total of $31,945 in payments from pharmaceutical and medical device companies, with $3,336 received in 2024. These payments were reported across 59 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($15,989).
As a Medicare-enrolled provider, Ko has provided services to 1,191 Medicare beneficiaries, totaling 2,019 services with total Medicare billing of $218,238. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology
- Location San Francisco, CA
- Active Since 04/14/2006
- Last Updated 09/11/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1851355853
Products in Payments
- TECENTRIQ (Biological) $5,716
- Tecentriq (Biological) $3,709
- FYARRO (Drug) $2,878
- SOMATULINE DEPOT (Drug) $2,450
- Abraxane (Drug) $2,385
- Lenvima (Drug) $2,355
- IMFINZI (Drug) $1,198
- St. Jude Medical (Device) $539.40
- Imbruvica (Drug) $500.00
- Orserdu (Drug) $101.35
- Optune (Device) $100.09
- Non-Covered Product (Drug) $78.03
- ACTHAR (Biological) $33.25
- IBRANCE (Drug) $31.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in San Francisco
Dr. Fred Cohen, M.d, M.D
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
John Teerlink, M.d, M.D
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Kenneth Binmoeller, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Dr. Hope Rugo, Md, MD
Internal Medicine — Payments: $881,117
Internal Medicine $881,117
Dr. Steven Harris, M.d, M.D
Internal Medicine — Payments: $806,637
Internal Medicine $806,637
Dr. Kenneth Colley, Md, MD
Internal Medicine — Payments: $732,736
Internal Medicine $732,736